Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.
about
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusPathogenicity and transmissibility of North American triple reassortant swine influenza A viruses in ferretsCross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.Advances in influenza vaccination.Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.Influenza vaccines: from surveillance through production to protection.Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferretsStructural basis of influenza virus neutralization.Targets for the induction of protective immunity against influenza a viruses.The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferretsPassive immune neutralization strategies for prevention and control of influenza A infections.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designCan immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complicationsA high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidaseRandomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.Seasonal trivalent inactivated influenza vaccine does not protect against newly emerging variants of influenza A (H3N2v) virus in ferretsAntibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time.Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.Antibodies directed towards neuraminidase N1 control disease in a mouse model of influenza.NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
P2860
Q27316330-5A234D00-A74C-4F87-B815-4DF534B58A1EQ28386553-6F1885B8-D2F1-456E-A3AC-23CA33CA8949Q30359842-8545CF91-F07F-4B42-A173-2E3A47C1BB74Q30364315-E0554718-AAEC-4516-9F3C-83D265EAAABAQ30378263-5D04191D-87D0-4BE6-AEC5-885019DF5759Q30382650-B87A346E-BF8B-420F-B674-566C9124395DQ30385118-FD08F3C9-7EB9-4159-B2E7-9AB3D14EB3B6Q30392305-E2C811F2-25EA-44C7-B047-D2691D5BFB83Q30398754-B3880164-8695-49E3-8CAB-B0D478E904CBQ30408100-D65344B2-F3EF-4F6F-880B-D2D2202F60CAQ30413023-3724BFBF-A7F9-4E46-9E6F-3E19A213953DQ30413158-671DAEE7-C15B-47F9-9443-961B7622B0F2Q30416502-0A0DC3DC-ADA1-4B8E-9854-DF9728C091D0Q33273605-EDB1649D-C1B6-48F4-916E-17265E0DF154Q33769373-1D5EA400-703B-416A-90AC-6896F497E2EBQ33782762-512EF3B7-70FD-4B52-A3FC-F192761C7B34Q33820732-97BE7C8C-BAAF-455C-8BA4-A510F7F208D2Q34761957-122F27F7-2CF5-4CFD-8B96-69CA55F0DFF1Q35826733-8192F7C1-7A9E-425D-8213-CD236C75D431Q36075789-15D36108-F2F3-4C6A-8DC2-69EDE7044BB1Q36452689-84CFA503-1A0E-4352-AC62-18F874BDBE39Q36462309-95F5E298-2CED-42B0-8654-9B0B328BC72FQ36559615-67CE4552-4610-4166-809C-FF9197B9A377Q37591325-4431CA15-55C2-45AA-95CB-567DE5DB3EE4Q41918783-249D5C74-5187-4FDE-9767-D5CD01960328Q41933365-0BB9444A-132B-4745-B5F7-C1A3003FF253Q47426452-67D33229-53D6-4F8F-BAAC-2F96ADFB8699Q52609074-F5B97CF0-4820-40F1-B502-D866CA9F77F6
P2860
Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Neuraminidase-specific antibod ...... e in young and elderly adults.
@en
Neuraminidase-specific antibod ...... e in young and elderly adults.
@nl
type
label
Neuraminidase-specific antibod ...... e in young and elderly adults.
@en
Neuraminidase-specific antibod ...... e in young and elderly adults.
@nl
prefLabel
Neuraminidase-specific antibod ...... e in young and elderly adults.
@en
Neuraminidase-specific antibod ...... e in young and elderly adults.
@nl
P2093
P2860
P1476
Neuraminidase-specific antibod ...... ne in young and elderly adults
@en
P2093
B E Johansson
D C Powers
E D Kilbourne
P2860
P304
P577
1996-09-01T00:00:00Z